Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment

• Published in: Frontiers in immunology Vol. 12; p. 838082
• Main Authors: Wang, Jiewen, Kang, Guangbo, Yuan, Haibin, Cao, Xiaocang, Huang, He, de Marco, Ario
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 18.01.2022
• Subjects: Animals; Autoimmune Diseases - immunology; Autoimmune Diseases - therapy; Communicable Diseases - immunology; Communicable Diseases - therapy; Humans; imaging; Immunology; Immunomodulation; intrabodies; Molecular Imaging; Molecular Targeted Therapy; nanobody functionalization; nanobody multimers; Neoplasms - diagnostic imaging; Neoplasms - immunology; Neoplasms - therapy; Recombinant Proteins - chemistry; Recombinant Proteins - immunology; Recombinant Proteins - therapeutic use; Single-Domain Antibodies - chemistry; Single-Domain Antibodies - immunology; Single-Domain Antibodies - therapeutic use; intrabodies; immunomodulation; nanobody multimers; nanobody functionalization; imaging
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2021.838082

Recombinant antibodies such as nanobodies are progressively demonstrating to be a valid alternative to conventional monoclonal antibodies also for clinical applications. Furthermore, they do not solely represent a substitute for monoclonal antibodies but their unique features allow expanding the applications of biotherapeutics and changes the pattern of disease treatment. Nanobodies possess the double advantage of being small and simple to engineer. This combination has promoted extremely diversified approaches to design nanobody-based constructs suitable for particular applications. Both the format geometry possibilities and the functionalization strategies have been widely explored to provide macromolecules with better efficacy with respect to single nanobodies or their combination. Nanobody multimers and nanobody-derived reagents were developed to image and contrast several cancer diseases and have shown their effectiveness in animal models. Their capacity to block more independent signaling pathways simultaneously is considered a critical advantage to avoid tumor resistance, whereas the mass of these multimeric compounds still remains significantly smaller than that of an IgG, enabling deeper penetration in solid tumors. When applied to CAR-T cell therapy, nanobodies can effectively improve the specificity by targeting multiple epitopes and consequently reduce the side effects. This represents a great potential in treating malignant lymphomas, acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma and solid tumors. Apart from cancer treatment, multispecific drugs and imaging reagents built with nanobody blocks have demonstrated their value also for detecting and tackling neurodegenerative, autoimmune, metabolic, and infectious diseases and as antidotes for toxins. In particular, multi-paratopic nanobody-based constructs have been developed recently as drugs for passive immunization against SARS-CoV-2 with the goal of impairing variant survival due to resistance to antibodies targeting single epitopes. Given the enormous research activity in the field, it can be expected that more and more multimeric nanobody molecules will undergo late clinical trials in the next future. Systematic Review Registration.